# Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

> **NCT05640830** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kangbuk Samsung Hospital** · enrollment: 47 (estimated)

## Conditions studied

- HER2-positive Advanced Gastric Cancer

## Interventions

- **DRUG:** trastuzumab, bevacizumab with paclitaxel (triple combination)

## Key facts

- **NCT ID:** NCT05640830
- **Lead sponsor:** Kangbuk Samsung Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640830, "Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05640830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*